Grazoprevir

Basic Information


CAS ID: 1350514-68-9
Molecular Formula: C38H50N6O9S
Molecular Weight: 766.9 g/mol
Monoisotopic Mass: 766.336 g/mol
Class: Small Molecule
Natural Product: No
Other Names: GRAZOPREVIR
Analysis: Drug repositioning mechanism analysis

O N O O NH O N O NH O NH S O O O N


Compound Structure and Identifier


InChI: InChI=1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1 See All
InChI Key: OBMNJSNZOWALQB-NCQNOWPTSA-N
Smiles: COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N5C[C@@H](C[C@H]5C(=O)N[C@@]6(C[C@H]6C=C)C(=O)NS(=O)(=O)C7CC7)Oc3nc2c1)C(C)(C)C See All
Molfile: Download


Related Target



Related Fibrosis Property


Trial Record 1

ClinicalTrial ID NCT03186365 Disease Liver fibrosis
Phase Phase 3 Status Completed
First Received June 14, 2017 Last Verified January 9, 2019
Sponsor Kaohsiung Medical University Chung-Ho Memorial Hospital

Trial Record 2

ClinicalTrial ID NCT03143998 Disease Liver fibrosis
Phase Phase 4 Status Withdrawn
First Received May 8, 2017 Last Verified November 9, 2017
Sponsor Merck Sharp & Dohme Corp.

Trial Record 3

ClinicalTrial ID NCT03037151 Disease Liver fibrosis
Phase Phase 4 Status Recruiting
First Received January 31, 2017 Last Verified October 29, 2018
Sponsor The HIV Netherlands Australia Thailand Research Collaboration

Trial Record 4

ClinicalTrial ID NCT03222167 Disease Liver fibrosis
Phase Phase 3 Status Not yet recruiting
First Received July 19, 2017 Last Verified August 7, 2017
Sponsor Institute Of Cardiology & Internal Diseases, Kazakhstan

Trial Record 5

ClinicalTrial ID NCT02732405 Disease Liver fibrosis
Phase Phase 3 Status Unknown
First Received April 8, 2016 Last Verified April 8, 2016
Sponsor Istituto Clinico Humanitas

Related Link


PubChem: 44603531
ChEMBL: CHEMBL2063090